Clinical Trial Update: Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]

View source ↗

Summary

Phase 3 trial Pola-R-ICE vs R-ICE in second-line Diffuse Large B-Cell Lymphoma is currently active but not recruiting. The study evaluates adding polatuzumab ve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Polatuzumab Vedotin (Polivy) (polatuzumab vedotin)
• Rituximab (rituximab)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING